MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in London
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in
London
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Multiple Sclerosis Announced as Second Indication for MOR103
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present significant
recent developments and provide a full outlook on its partnered and proprietary
drug pipeline as well as a comprehensive technology update during today's R&D
Day to be held in London starting at 9.30 am GMT. A second event will be held in
New York on November 29, 2010 starting at 11.30 am EST. MorphoSys has built one
of the broadest antibody pipelines in the biotechnology industry with 12
clinical projects ongoing and a total of 76 distinct drug programs.
Today's event will be held at Berenberg's offices at 60 Threadneedle Street,
London, EC2R 8HP, UK and can be viewed via webcast at www.morphosys.com. The New
York event will be held at The W Hotel, 541 Lexington Avenue, New York, NY
10022, USA and registration is possible at www.morphosys.com/rnd-day2010.
New Announcements at Today's R&D Day include:
* Disclosure of multiple sclerosis as the second indication for the Company's
lead development program MOR103, a fully human HuCAL antibody targeting GM-
CSF. The decision is based on a compelling scientific rationale and
promising pre-clinical data. MorphoSys expects to start a phase 1b trial in
multiple sclerosis with MOR103 in H2 2011.
* Preclinical data for MOR103 in both rheumatoid arthritis (RA) and multiple
sclerosis and an update on imaging/biomarkers used in the ongoing phase
1b/2a study in RA.
* Preclinical data for MOR202, a HuCAL antibody targeting CD38 to treat
multiple myeloma. A clinical trial application (CTA) to initiate a phase
1/2a trial with MOR202 in patients with relapsed/refractory myeloma has been
filed in Europe and the Company expects to dose the first patient in H1
2011.
* An update on MOR208, an Fc-enhanced anti-CD19 antibody to treat B-cell
malignancies. The program was in-licensed from Xencor in June 2010 and is
currently in a phase 1 clinical trial in relapsed or refractory CLL/SLL in
the US with patient enrollment expected imminently.
* An update on the Company's partnered pipeline, comprising now five partnered
projects in phase 2 clinical trials. Roche has started a phase 2 clinical
trial with Gantenerumab, a HuCAL antibody against amyloid-beta to treat
Alzheimer's disease.
* The latest technology developments, such as the recently announced
optimization platform arYla(TM), as well as additional modules for more
efficient selection and screening of antibody libraries.
"MorphoSys has established a significant proprietary product portfolio and its
clinical programs MOR103, MOR202 and MOR208 are on track to generate lucrative
out-licensing opportunities in the years ahead," commented Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys. "Our decision to develop
MOR103 in a second indication beyond rheumatoid arthritis, namely multiple
sclerosis, is based on a compelling scientific rationale and promising pre-
clinical data and we are intrigued by its prospects. I'm excited about the
progress we've made in Proprietary Development since I joined MorphoSys two
years ago."
"The commercial opportunity for therapeutic antibodies is enormous. As we learn
more about this class of drugs we are identifying ways of making antibodies that
will be superior to currently available drugs, and our strategy is to command
and apply a range of technologies to deliver these new therapies." commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys. "MorphoSys has now
established a suite of technologies to enable generation of the best possible
therapeutic antibodies and continues to set industry standards with its new
arYla(TM) antibody optimization technology."
MorphoSys will hold a public conference call today at 09:30 GMT (10:30 CET) to
give an update on its partnered pipeline, proprietary portfolio and recent
technology developments.
Dial-in number for the Conference Call (listen-only):
Germany: +49 (0) 89 24443 2975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 212 999 6659
Please dial in 10 minutes before the beginning of the conference.
In addition, MorphoSys offers participants the opportunity to follow the
presentation through a simultaneous slide presentation online
athttp://www.morphosys.com.
A live webcast, slides, webcast replay and transcript will be made available
at http://www.morphosys.com.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered
trademarks of MorphoSys. arYla(TM) is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
?
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1465353]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
http://hugin.info/130295/R/1465353/403558.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 25.11.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 49091
Anzahl Zeichen: 9174
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Presents Comprehensive Pipeline and Technology Update at R&D Day in London"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
